With the breakthroughs in human science and the rapid development of technology, the concept of human beings towards diseases has shifted from disease treatment to disease prevention, and the medical treatment solutions have also shifted from closed and conservative to diversified and innovative, especially after the baptism of the COVID-19 virus pandemic, which has accelerated the development of breakthrough therapies such as mRNA vaccines or cellular therapies for application in medicine, and has prompted the rapid integration of ICT-enabled solutions into the scene of healthcare needs. This has also led to the rapid integration of ICT-enabled technologies into the healthcare landscape.

The biotechnology-pharmaceutical industry has always been one of the most important aspects of Taiwan's industries, and it is even regarded as the future economic lifeline of Taiwan, the new generation of the protector of the country. After many years of policy support and international integration, and after stumbling in the capital market and growing in the international market, a number of manufacturers have already obtained drug certificates overseas, and in the gold-mining game, whether it is good to mine gold (new drug development) or to sell mining tools or mining technology services (commissioned design and manufacturing services/clinical trial services), or to sell peripheral services (testing or research services), it depends on the core strengths and market strengths of manufacturers and the market. In the gold mining competition, whether it is better to mine gold (new drug development), sell mining tools or mining technology services (commissioned design and manufacturing services/clinical trial services), or sell peripheral services (testing or scientific research services) depends on the core strengths of the manufacturer and the opportunities and chances under the competition in the market. If the candidate drug obtains the marketing license, the results of the efficacy ranking competition, as well as the penetration rate of the drug in the market channel and market share in each country, will also be a choice under the management of opportunities and risks, and the only constant is that the hard truth is still the drug and the drug license will be the only thing that remains unchanged. The only thing that remains unchanged is that the drugs and medical technology services must be good enough to meet the medical needs of the customers.

In the post epidemic (Long COVID) era, the actual application of technology to the medical scene, technology, medical and health bundled together more closely, technology to participate in the future changes in health care, the integration of technology and wisdom empowerment is a necessary element, initiated by the biomedical data, translation (interpretation) of health information, to provide health knowledge to assist, the use of health wisdom interpretation, technology empowerment to health promotion, prevention, precision medicine and disease care services, combined with the introduction of medical products such as pharmaceuticals, medical devices, health supplies, nutritional foods and health aids, to enhance the quality of medical services, home care, health aids and other services, to enhance the quality of health care services, home care. The services of health promotion, preventive medicine, precision medicine and disease care, combined with the introduction of medical products such as pharmaceuticals, medical devices, healthcare products, nutritional food and healthcare aids, etc., to enhance the quality of medical services, home care and recreational services, leisure and fitness healthcare and healthcare consulting and management, which can be radiated to a wider range of dimensions of care and unsatisfied healthcare needs in different scenarios, how to select the topics for linking up with the healthcare service chain and how to participate in the healthcare services chain. How to choose the topic to connect the healthcare service chain and how to participate in the construction of the ecosystem of the healthcare industry will also be a major challenge for medical technology enterprises.

Looking ahead to 2023, Ji-Pu recommends that Taiwan's health industry trends and business opportunities can focus on the following points: 1. When will business opportunities open up as new medicines converge with the international market? 2. Technology companies are actively involved in the medical and biotechnology fields, how can they show results on the ground? And 3. How can emerging therapies turn the corner in the post-pandemic era? What can Taiwan do about cell therapy or gene therapy?